Pfizer Inc.

PFE·NYSE·Healthcare
Compare
30.79+0.79 (+2.63%)today
At close: Nov 4, 4:02 PM EST · May be delayed up to 15 min · USD
Pre-market30.95+0.16 (+0.52%)

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close30.00
Open30.75
Day range30.0430.90
52-week range23.6231.06
Off day high−0.36%
Off 52-week high−0.87%
Volume48.25M
Avg. volume (3M)33.77M
Market cap175.50B
EPS (TTM)0.7000
Forward P/E10.58
P/E ratio (TTM)43.99
Dividend yield5.59% (1.72)
Beta (5Y)0.30
Shares outstanding5.70B
Short interest2.42% of float
Earnings dateNov 3, 2026 (est.)
Analyst target29.26
Profit margin6.80%

Against its peers

Compare in full ›
PFE AZN MRK SNY 0QYQ.IL BMY
Market cap 175.50B 293.14B 370.96B 113.74B 215.56B 131.21B
P/E (TTM) 44.0 26.7 151.9 23.6 39.8 14.2
Forward P/E 10.6 16.7 16.7 8.9 — 9.6
Price/book 2.1 5.7 8.9 1.4 10.2 5.6
Dividend yield 5.59% 1.69% 2.26% 5.10% 3.81% 3.93%
1-year change +21.90% +13.30% +71.43% −7.49% +38.91% +32.80%
Today +2.63% +2.79% +3.93% +4.72% +0.58% +4.02%

The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.

Latest news

All PFE news ›
Seeking Alpha·Positive

Pfizer: The Portfolio Transformation Is Gaining Momentum

Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead of the LOE cliff. Learn more about PFE stock here. - Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive…

Trefis·Negative

Why Did Pfizer Stop Talking Up This Business?

Pfizer Now Talks Up Drugs It Launched Or Bought During the November 3 call, management focused on products Pfizer either launched or acquired, including Padcev, Nurtec and Lorbrena. Management also explained the strategy behind them:…

The Globe and Mail·Positive

Pfizer (PFE) Gets a Hold from J.P. Morgan

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. Schott covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Pfizer. According to TipRanks,…

Moneycontrol·Positive

Buy Pfizer; target of Rs 4800: ICICI Securities

Moneycontrol.com Buy Pfizer; target of Rs 4800: ICICI Securities ICICI Securities's research report on Pfizer Pfizer delivered a revenue beat in Q2FY27, though EBITDA and PAT were in line with our expectations. Revenue advanced ~13.2%…

The Motley Fool·Positive

Pfizer: 3 Key Takeaways for Long-Term Investors

The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue. New treatments and recent acquisitions are generating immediate sales growth that buffers…

From the 4Search news index, newest first.

In the news

400mentions in 30 days
257with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance